Acadia Pharmaceuticals gets U.S. patent allowance for trofinetide dosing
The company said a U.S. patent covering weight-banded dosing of trofinetide has been allowed, extending U.S. patent protection to March 2041.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Acadia Pharmaceuticals gets U.S. patent allowance for trofinetide dosing
The allowance covers weight-banded dosing of trofinetide for Rett syndrome and is expected to extend U.S. protection to March 28, 2041, from July 2036.
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled “Methods and Compositions for Treatment of Rett Syndrome.” The Notice of Allowance indicates that…